Beverly Hills Private Wealth’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.87M Buy
20,350
+775
+4% +$287K 1.5% 17
2026
Q1
$5.73M Buy
19,575
+2,698
+16% +$887K 0.95% 26
2025
Q4
$5.92M Sell
16,877
-1,469
-8% -$496K 1.01% 22
2025
Q3
$5.93M Buy
18,346
+3,800
+26% +$1.18M 1.05% 17
2025
Q2
$5.66M Buy
14,546
+994
+7% +$400K 1.06% 17
2025
Q1
$5.89M Buy
13,552
+1,755
+15% +$705K 1.17% 14
2024
Q4
$4.35M Buy
11,797
+2,459
+26% +$1.03M 0.88% 23
2024
Q3
$4.86M Buy
9,338
+1,895
+25% +$1.01M 0.98% 20
2024
Q2
$4.03M Buy
7,443
+1,346
+22% +$711K 0.88% 26
2024
Q1
$3.16M Buy
6,097
+1,510
+33% +$751K 0.73% 30
2023
Q4
$2.16M Buy
4,587
+510
+13% +$236K 0.56% 48
2023
Q3
$1.78M Sell
4,077
-3,049
-43% -$1.38M 0.53% 53
2023
Q2
$3.3M Buy
7,126
+3,703
+108% +$1.71M 0.54% 57
2023
Q1
$1.57M Buy
3,423
+524
+18% +$249K 0.49% 59
2022
Q4
$1.49M Buy
+2,899
New +$1.47M 0.65% 50

Other funds holding ELV

Beverly Hills Private Wealth's ELV Position: Q2 2026 in Review

Beverly Hills Private Wealth increased its Elevance Health (ELV) stake by 4% in Q2 2026, buying an estimated $287K and bringing the position to 20,350 shares worth $7.87M. The position accounts for 1.5% of the portfolio, ranked #17.

Beverly Hills Private Wealth first reported a position in ELV in Q4 2022 and has held it in 15 quarters since. 1,612 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Beverly Hills Private Wealth held 20,350 shares of Elevance Health worth $7.87M as of Q2 2026.
  • Beverly Hills Private Wealth bought 775 Elevance Health shares in Q2 2026, an estimated $287K.
  • Elevance Health made up 1.5% of Beverly Hills Private Wealth's portfolio in Q2 2026, its #17 holding.
  • Beverly Hills Private Wealth first reported a position in Elevance Health in Q4 2022 and has held it in 15 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Beverly Hills Private Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.